Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045500 · ClinicalTrials.gov registry record · Phase 1
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00045500: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00045500 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045500, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: UCN-01 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with prednisone may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with prednisone in treating patients who have refractory solid tumors or lymphoma.
Interventions
- DRUG prednisone
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00045500 record still lists
NCT00045500 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00045500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045500 about?
NCT00045500 is a clinical study titled "UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma". RATIONALE: UCN-01 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with prednisone may kill more cancer cells. PURPOSE: Phase I...
What is the current status of trial NCT00045500?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-06.
What interventions are being tested in trial NCT00045500?
The interventions under investigation include: prednisone (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00045500?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia